Dr Reddy’s profit down 14% on low Lenalidomide US sales
In the October to December period of FY26, DRL recorded a 12 per cent Y-o-Y drop in revenue from North America to Rs 2,964 crore from Rs 3,383 crore due to continued price erosion in Lenalidomide. Photograph: Reuters In contrast,